Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 Debt-to-Equity is 7.21 as of Dec. 2025, which is 14% above its 10-year median of 6.32. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, Labiana Health ranks worse than 99.01% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Labiana Health's Debt-to-Equity or its related term are showing as below:
XMAD:LAB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 2.71 Med: 6.32 Max: 12.34
Current: 7.21
During the past 6 years, the highest Debt-to-Equity Ratio of Labiana Health was 12.34. The lowest was 2.71. And the median was 6.32.
XMAD:LAB's Debt-to-Equity is ranked worse than 99.01% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs XMAD:LAB: 7.21
Labiana Health (XMAD:LAB) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Labiana Health Debt-to-Equity Related Terms
Labiana Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Labiana Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Labiana Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Debt-to-Equity of 7.21 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Labiana Health and its competitors. This is 14% above median its historical median of 6.32. Over the past decade, Labiana Health's Debt-to-Equity has ranged from 2.71 to 12.34. According to the industry distribution chart, Labiana Health ranks #804 out of 812 companies in the Drug Manufacturers industry, placing it in the top 99%.
Is Labiana Health's Debt-to-Equity too high?
Labiana Health's current Debt-to-Equity of 7.21 is 14% above median its 10-year median of 6.32. Over the past 10 years, this metric has ranged from a low of 2.71 to a high of 12.34. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Labiana Health's value of 7.21 is 2570.4% above this industry median. Based on the distribution chart, Labiana Health ranks #804 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #804 out of 812 companies for Debt-to-Equity. This places Labiana Health in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Labiana Health's value of 7.21 is 2570.4% above this benchmark. Historically, Labiana Health's own Debt-to-Equity has ranged from 2.71 to 12.34 over the past decade. While the company's 10-year median is 6.32 vs. the industry median of 0.27, Labiana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Debt-to-Equity of 7.21 is 2570.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Debt-to-Equity is 7.21, which is 14% above median its own 10-year median of 6.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Debt-to-Equity is 7.21, which is 14% above median its 10-year median of 6.32 and 2570.4% above the Drug Manufacturers industry median of 0.27. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Debt-to-Equity is 7.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Debt-to-Equity: 7.21 (14% above median its 10-year median of 6.32)
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 2570.4% above the Drug Manufacturers median (#804 of 812)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
